Editas Medicine, Inc. (EDIT)
After hours:
| Previous close | 5.56 |
| Open | 5.52 |
| Bid | 5.29 x 300 |
| Ask | 5.35 x 800 |
| Day's range | 5.25 - 5.69 |
| 52-week range | 4.91 - 11.91 |
| Volume | |
| Avg. volume | 2,012,611 |
| Market cap | 457.243M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.07 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.36 |
GlobeNewswireEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medic
Insider MonkeyEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.76 EPS, expectations were $-0.63. Editas Medicine, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
ZacksEditas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
